VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
April 17, 2018 08:00 ET | VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationLow-dose study arm: enrollment completeIntermediate-dose study arm: enrollment...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Changes to its Board of Directors
January 26, 2018 16:15 ET | VBI Vaccines, Inc.
Sam Chawla, of Perceptive Advisors, to resign from VBI Board of DirectorsTomer Kariv, Chairman and CEO of The Pontifax Group, to replace Ran Nussbaum on VBI’s Board of Directors CAMBRIDGE, Mass.,...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine
December 19, 2017 08:00 ET | VBI Vaccines, Inc.
Patient dosing commenced on December 18, 20174,800 subjects across two Phase 3 studies: PROTECT and CONSTANT 15-month program - headline data expected Q2 2019 CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
December 12, 2017 08:00 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will present at the BMO Capital Markets...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
November 10, 2017 08:00 ET | VBI Vaccines, Inc.
New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccinePoster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum
November 02, 2017 08:00 ET | VBI Vaccines, Inc.
Ran Nussbaum, managing partner and co-founder of The Pontifax Group, joins VBI Board of DirectorsPontifax’s participation in the recent financing was alongside investments from several new fundamental...
VBI-Vaccines-Vertical-Logo.png
VBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common Shares
October 31, 2017 08:30 ET | VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...